.jpg){kind=logo}
Accreditation
The American College of Medical Genetics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The American College of Medical Genetics and Genomics designates this live activity for a maximum of 19.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country. Non-physicians may request a certificate of attendance for their participation.
Continuing Education Information
CME, CCP, P.A.C.E.®, NSGC Educational Credits
P.A.C.E.®
ACMG is approved as a provider of continuing education programs in the clinical laboratory sciences by the American Society for Clinical Laboratory Science (ASCLS) Professional Acknowledgment for Continuing Education (P.A.C.E.®) Program.
ACMG is approved by the Florida Board of Clinical Laboratory Personnel as CE Provider (50-11878). This course is registered with CEBroker # 20-950650. ACMG is approved by the California Department of Health Services through the ASCLS P.A.C.E.®. This activity has been approved for 19.5 P.A.C.E.® CEU's.
National Society of Genetic Counselors (NSGC)
The National Society of Genetic Counselors (NSGC) has authorized ACMG to offer up to 1.95 CEUs or 19.5 Category 1 contact hours for the activity 2023 ACMG Annual Clinical Genetics Meeting. The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of genetic counselor certification and recertification.
NSGC Credits must be claimed by May 1, 2023. Educational credit requests after this date will not be accepted or reported to NSGC. ACMG will report claimed credits to NSGC on May 12th and you can expect certificates three weeks later. NSGC User IDs are required for all participants wishing to claim NSGC CEUs.
NSGC Credits must be claimed by May 1, 2023. Educational credit requests after this date will not be accepted or reported to NSGC. ACMG will report claimed credits to NSGC on May 12th and you can expect certificates three weeks later. NSGC User IDs are required for all participants wishing to claim NSGC CEUs.
All credits must be claimed by May 1, 2023.
Financial Disclosures
Accredited Continuing Education Financial Disclosure
The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.
ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
ACMG Education Policies
Please review the policies below regarding the ACMG Education program:
- Financial Disclosures and Mitigation Procedure
- ACMG Content Validation Policy
- ACMG Content Branding Policy
Program Committee and ACMG Staff*
The following have nothing to disclose.
| Amudhavalli, Shivarajan | Manolio, Teri |
| Barnett, Claudia | Mito, Yoshiko |
| Conboy, Erin | Muenke, Maximillian |
| Dahlroth, Jane | Radford, Jane |
| Elsea, Sarah | Rowsey, Ross |
| Freire, Penelope | Stover, Samantha |
| Gambello, Michael | Thompson, Katarzyna |
| Gosh, Rajarshi | Tischkowitz, Marc |
| Hoffman, Jodi | Wick, Myra |
| King, Jennifer | Williams, Marc |
| Kopp, Nathan | Zepeda Mendoza, Cinthya |
| Kulchak Rahm, Alanna |
All of the relevant financial relationships listed for these individuals have been mitigated.
| Program Committee Member | Financial Disclosure Relationship/Company |
| John A. Bernat, MD, PhD, FACMG | Research support for clinical trials: Avrobio, BioMarin Pharmaceutical Inc., Chiesi USA Inc, Idorsia Pharmaceuticals, Pfizer, Inc., SAB: Chiesi USA Inc, Sanofi, Takeda Pharmaceutical |
| Susan Berry, MD, FACMG | Reported disclosures and none are relevant to the content of this course. |
| Keith A. Eddleman, MD, FACMG | Reported disclosures and none are relevant to the content of this course. |